EGFR and laryngotracheoesophageal cleft: Additionally, LC patients received first-generation EGFR-TKI in studies of thymosin combined with targeted therapy, and variations in staging and EGFR-TKIs may be the reason why the findings of the two studies are completely dissimilar.